On January 2, 2026, GSK plc reported that David Redfern, President of Corporate Development, and Victoria Whyte, SVP & Company Secretary, acquired 790 ordinary shares each at £11.39 through options exercised from November 28, 2022. This filing is categorized under 'Changes in management or control' and reflects a positive sentiment about internal investment.